Despite reporting a Phase 3 win this summer, Pfizer terminated its hemophilia A gene therapy pact with Sangamo Therapeutics ...

Valo Health’s diabetic retinopathy drug failed to improve patients' symptoms in a Phase 2 study, and the company is now on ...

Axsome Therapeutics on Monday reported data for two Phase 3 studies in Alzheimer’s-related agitation, saying one trial ...

A decade after Bristol Myers Squibb first won approval for its PD-1 checkpoint inhibitor Opdivo, the cancer drug has been ...

WuXi Apptec will sell its Advanced Technologies unit to the US private equity firm Altaris for an undisclosed amount, a ...

BioNTech settles with NIH and UPenn over Comirnaty royalties, paying $750M to NIH and $400M to UPenn for 2020-2023, with ...

Applied Therapeutics CEO Shendelman exits; CFO Funtleyder becomes interim CEO after FDA rejects govorestat. Company withdraws ...

Amgen, Eli Lilly and UCB sued the federal government, claiming that several STD clinics getting drug discounts under the ...

Eli Lilly dominates obesity market, megadeals decline, I&I sector thrives, and FDA's setback in misinformation fight.

The Federal Trade Commission is praising an appeals court decision calling for Teva to delist five inhaler patents from the ...

The Centers for Medicare and Medicaid Services on Friday released detailed but heavily redacted explanations of how it ...

Bristol Myers Squibb's Sotyktu succeeds in Phase 3 psoriatic arthritis trials, as company leads TYK2 race against Takeda & ...